Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term follow-up of botaretigene sparoparvovec for X-linked retinitis pigmentosa due to RPGR variants
2024-511411-25-00Phase 3Authorised
- Sponsor
- MeiraGTx
- Start
- Aug 2022
- Modality
- Gene Therapies
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by MeiraGTx. Primary endpoints: Adverse events, Laboratory assessments and 2 more. Planned start Aug 2022; status: authorised.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on 2024-511411-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511411-25-00.